aTyr Pharma

aTyr Pharma FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of aTyr Pharma (ATYR) as of Nov 4, 2026 is 83.74 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 108.06 % — a change of -22.51% (lower).

FCF Conversion

83.74 %

YoY

-22.51%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of aTyr Pharma is 2025 83.74 % . FCF Conversion Rate (FCF/EBITDA) of aTyr Pharma was 2024 108.06 % . It decreases by -22.51% lower compared to the previous year.

The aTyr Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
91.72 USD
Jan 1, 2019
85.12 USD
Jan 1, 2020
95.56 USD
Jan 1, 2021
98.52 USD
Jan 1, 2022
96.01 USD
Jan 1, 2023
74.29 USD
Jan 1, 2024
108.06 USD
Jan 1, 2025
83.74 USD
The aTyr Pharma FCF Conversion history
YEARFCF ConversionYoY
83.74 %-22.51%
108.06 %+45.45%
74.29 %-22.61%
96.01 %-2.55%
98.52 %+3.10%
95.56 %+12.25%
85.12 %-7.19%
91.72 %+1.23%
90.60 %-1.95%
92.41 %+18.34%
78.09 %-17.59%
94.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

aTyr Pharma Stock analysis

What does aTyr Pharma do? aTyr Pharma Inc is a biotechnology company based in San Diego, California. Founded in 2005, the company has gained a lot of attention in recent years for its focus on developing drugs based on proteomics, the analysis of proteins. The idea for aTyr came from the realization that there are a variety of proteins that can be used as a basis for developing new drugs. The company has developed a unique proteomics platform that allows for the identification and utilization of previously undiscovered proteins to understand biological processes and develop new drugs for diseases. aTyr specializes in the discovery and development of proteins associated with rare but difficult-to-treat diseases. This includes rare muscle diseases and lung diseases. The company collaborates closely with clinicians and scientists to advance its research and development. aTyr's business model is based on the development of new drugs based on proteomics, with a focus on rare diseases that are often neglected. The goal is to improve the quality of life for patients by developing new and innovative drugs. aTyr has various divisions, including therapeutic proteins and diagnostics. The company has a number of drugs in development targeting different diseases. This includes Resolaris, a protein focused on rare muscle diseases, and ATYR1923, developed for the treatment of lung diseases. Resolaris is a novel protein targeting rare muscle diseases such as FSHD and LGMD. It is currently being tested in clinical trials and has the potential to significantly improve the quality of life for patients with these severe conditions. The company is also developing ATYR1923, a protein for the treatment of lung diseases such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Overall, aTyr Pharma is an innovative company focused on the development of novel drugs based on proteomics. With its unique proteomics platform, the company has the potential to identify and utilize previously undiscovered proteins to understand biological processes and develop new drugs for diseases. With its various divisions, including therapeutic proteins and diagnostics, the company has the potential to improve the treatment of rare and difficult-to-treat diseases and enhance the lives of patients worldwide. aTyr Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about aTyr Pharma stock

FCF Conversion Rate (FCF/EBITDA) of aTyr Pharma is 83.74 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of aTyr Pharma changed from 108.06 % to 83.74 %, representing a -22.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) aTyr Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s aTyr Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — aTyr Pharma

All Key Metrics — aTyr Pharma